Hemab Therapeutics Secures $157M Series C Funding to Advance Rare Bleeding Disorder Treatments
Hemab Therapeutics, a biotech company focused on developing treatments for rare bleeding disorders, has successfully raised $157 million in a Series C funding round. The oversubscribed financing, led by Sofinnova Partners, positions Hemab to accelerate its ambitious pipeline and advance clinical candidates for underserved conditions such as Glanzmann thrombasthenia and von Willebrand disease.
Funding Boost for Innovative Therapeutics
The Series C round saw participation from both existing and new investors, including Novo Holdings, RA Capital Management, Rock Springs Capital, Qatar Investment Authority, and Avoro Capital Advisors. This substantial influx of capital underscores growing investor confidence in Hemab's approach to addressing rare bleeding disorders.
CEO Benny Sorenson, M.D., Ph.D., emphasized the company's vision, stating, "The quality of our investor syndicate and this significant financing validate our approach and enable us to continue building what we believe will become the ultimate clotting company." Sorenson highlighted Hemab's deep domain expertise in clotting science and the team's proven capabilities in advancing programs from early development through approval and commercialization.
Advancing Clinical Candidates
Hemab's pipeline is spearheaded by two key clinical candidates:
-
Sutacimig: A bispecific antibody in mid-stage development, positioned as the first prophylactic treatment for Glanzmann thrombasthenia. In a Phase 2 study, sutacimig demonstrated clinically meaningful bleeding reduction. The company plans to initiate a pivotal trial for Glanzmann thrombasthenia next year and expand testing to Factor VII deficiency.
-
HMB-002: A monovalent antibody being developed as a bleeding prophylactic for von Willebrand disease. Early-stage studies have shown promising results, with the drug directly targeting the underlying pathophysiology of the disease by increasing both Von Willebrand Factor and Factor VIII levels.
The new funding will support the advancement of HMB-002 into a registration study and fuel the development of additional pipeline candidates, including HMB-003, slated for clinical development in 2026.
Strategic Focus on Underserved Blood Disorders
Hemab's strategy centers on addressing rare bleeding disorders that have seen limited innovation due to smaller market sizes and complex bioengineering challenges. The company aims to provide comprehensive solutions for patients with high unmet needs, focusing on conditions such as Glanzmann thrombasthenia, von Willebrand disease, and Factor VII deficiency.
Joe Anderson, Ph.D., partner at Sofinnova Partners and newly appointed board member of Hemab, praised the company's approach: "Hemab's deep scientific excellence and strong clinical execution make it a standout company in the biotech landscape."
As Hemab continues to build its pipeline, it remains committed to its "1-2-5" strategy, now aiming to advance five development projects by 2025. With this latest funding round, Hemab Therapeutics is well-positioned to drive innovation in the treatment of rare bleeding disorders and potentially transform patient care in this underserved therapeutic area.
References
- Hemab collects another $157M to go after ‘underserved’ blood diseases
The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation disorders company,” its CEO said.
- Hemab, working to build 'ultimate clotting company,' raises $157M series C for bleeding disorder ambitions
The company will use the fresh funding to build out its pipeline and advance its clinical candidates for Glanzmann thrombasthenia and von Willebrand disease.
Explore Further
What is the background and professional experience of Hemab Therapeutics' executive team, specifically CEO Benny Sorenson?
What are the highlights and competitive advantages of Hemab's core pipeline, including Sutacimig and HMB-002?
What clinical data support the efficacy of Sutacimig and HMB-002 in addressing rare bleeding disorders?
Who are the main competitors in the rare bleeding disorder treatment space, and how does Hemab differentiate itself?
What is the target market size for Glanzmann thrombasthenia and von Willebrand disease treatments, and how does Hemab plan to capture these markets?